The present Competitive Intelligence Report about Antibody Therapy of
Inflammatory and Autoimmune Diseases provides a competitor evaluation in the
field of antibody therapeutics used or being developed for treatment of
rheumatoid arthritis, psoriasis, Crohn' s disease, ulcerative colitis, multiple
sclerosis, asthma and other autoimmune diseases as of December 2010. Purchase
of the downloadable pdf report includes a 6-month online access to the data of
the report and any updates since the publication date. Credentials to access
the database will be sent by e-mail and allow online work with the project
data to print or export an individual report.
Inflammatory and autoimmune diseases are one of the major indication areas for
the use of therapeutic antibodies. The commercial success of anti-TNF
antibodies highlights the broad applicability of inflammatory targets to
develop antibody therapeutics. Sales of anti-inflammatory and anti-autoimmune
antibodies in 2009 exceeded US$ 21 bln. Inflammatory diseases with significant
commercial potential as demonstrated by approvals of antibody therapeutics are
rheumatoid arthritis and related diseases (psoriatic arthritis, ankylosing
spondylitis, juvenile arthritis), psoriasis, Crohn' s disease and ulcerative
colitis, but also multiple sclerosis and asthma. Rare indications such as
paroxysmal nocturnal hemoglubinuria turned out to be attractive markets for
anti-inflammatory antibody therapy. Among the emerging indications for
anti-inflammatory antibody therapy are systemic lupus erythematosus. The rare
autoimmune diseases benefit from antibodies approved for lead indications in
follow-up programs, at least for clinical evaluation.
The report includes a compilation of currently active projects in research and
development of antibody therapeutic for treatment of inflammatory and
autoimmune diseases. In addition, the report lists company-specific R&D
pipelines of anti-inflammatory and anti-autoimmune antibodies. Competitor
projects are listed in a tabular format providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Corporate Anti-Inflammatory and Anti-Autoimmune Antibodies R&D Pipelines
Abbott
AbGenomics
Ablynx
Acorda Therapeutics
Affimed Therapeutics
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Amgen
Anthera Pharmaceuticals
Apexigen
Argos Therapeutics
Astellas Pharma
AstraZeneca
Avaxia Biologics
Bayer Schering Pharma
Bio Mabs
Bio Products Laboratory
Biocon
Biogen Idec
BioLex
Biotest
BioTie Therapies
Biovitrum
BioWa
Boehringer Ingelheim
Boryung
Bristol-Myers Squibb
Celltrion
Celgene
Centocor (J&J)
Cephalon
Ception Therapeutics
Cipla
Cornerstone Therapeutics
Compugen
Dream Pharma
Eisai
Elan
Emergent Biosolutions
EMS
Epistem
Femta Pharmaceuticals
Genaera
Genentech
Genexine
Genmab
Genzyme
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Green Cross
Hadasit Bio-Holdings
Hospira
Human Genome Sciences (HGS)
Hunter Immunology
iCo Therapeutics
Immunomedics
InNexus Biotechnology
Inotek Pharmaceuticals
Japan Tobacco
Kaketsuken
KaloBios Pharmaceuticals
Kyowa Hakko Kirin Pharma
LG Life Science
Ligand Pharmaceuticals
Lilly
Mab Pharm
MacroGenics
MaimoniDex
Merck & Co.
Micromet
Miltenyi Biotec
Mitsubishi Tanabe Pharma
Morphosys
MRC Technology
NasVax
Nycomed
Novartis
NovImmune
Novo Nordisk
Otsuka Pharmaceuticals
PanGenetics
PDL BioPharma
Pfizer
Protalix Biotherapeutics
Regeneron
Roche
Sanofi-Aventis
Santen
Seikagaku
Selexys Pharmaceuticals
Shanghai Biomabs Pharmaceuticals
Shanghai C Guojian Pharmaceutical
Shenyang Sunshine Pharmaceutical Corporation
SK Chemicals
Symphogen
Takeda Pharmaceutical
Talecris Biotherapeutics
Taligen Therapeutics
TcL Pharma
Teijin
Teva Pharmaceutical Industries
Therapeutic Proteins Inc
Tolerx
Trillium Therapeutics
UCB Pharma
University of Viena
Vaccinex
XOMA
Yuhan Co.
Zenotech Laboratories
Competitor Analysis: Antibody Therapy of Inflammatory and Autoimmune Diseases published by La Merie Publishing in December 22, 2010. This report consists of 172 Pages and the price starts from US $ 1184.
